Belzutifan

Belzutifan significantly improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma, according to results of a randomized phase 3 trial.

The FDA approved belzutifan for treatment of adults with advanced renal cell carcinoma.

MADRID — Moshe Ornstein, MD, discussed the results of LITESPARK-005 presented at ESMO Congress in a video interview with Healio.

NASHVILLE, Tenn. — Belzutifan exhibited efficacy at two doses for patients with advanced clear cell renal cell carcinoma, according to randomized phase 2 study results presented at International Kidney Cancer Symposium: North America.

MADRID — In this video with Healio, Tian Zhang, MD, talked about “the bench-to-bedside journey of belzutifan” highlighted in the LITESPARK-005 study.

MADRID —Tian Zhang, MD, discussed the positive results presented at ESMO Congress on use of belzutifan combined with cabozantinib for patients with advanced clear cell renal cell carcinoma.

MADRID — Toni Choueiri, MD, talked with Healio about some of the new kidney cancer data “that could be practice-changing and, for sure, practice-informing” presented at ESMO Congress.

MADRID — In this video, Sumanta (Monty) Pal, MD, FASCO, shared his excitement about belzutifan data, a “big development” of ESMO Congress, in the renal cell carcinoma space.

Belzutifan prolonged PFS compared with everolimus for certain patients with advanced renal cell carcinoma, according to topline data released by the agent’s manufacturer.

In this video, Brad McGregor, MD, clinical director of Dana-Farber Cancer Institute's Lank Center for Genitourinary Cancer, discussed the rise of hypoxia-inducible factor-2 inhibitors to treat renal cell carcinoma.